Auryxia was Akebia Therapeutics’s largest product and service line in fiscal 2025, bringing in $181.54M of $235.09M (77%).
| Product and Service | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2020 | FY 2021 | FY 2022 | FY 2022 | FY 2022 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International Collaboration & License Agreement | — | — | — | — | — | — | — | |||||||||||||||
| Auryxia | — | — | — | — | $170.30M | $152.18M | $181.54M | |||||||||||||||
| Product Revenue, Net | $41.45M | $84.68M | $127.39M | $176.95M | $170.30M | $152.18M | — | |||||||||||||||
| License, Collaboration & Other Revenue | — | — | — | $104.77M | $10.97M | $5.37M | $5.66M | |||||||||||||||
| Vafseo | — | — | — | — | — | — | $45.79M | |||||||||||||||
| License & Service | — | — | — | — | — | — | — | |||||||||||||||
| Regulatory Milestone, Approval Of Vadadustat In Japan | — | — | — | — | — | — | — | |||||||||||||||
| License Collaboration & Other Revenue, Royalties | — | — | — | — | $2.00M | $1.90M | $1.80M | |||||||||||||||
| License | — | — | — | — | $1.00M | — | — | |||||||||||||||
| Supply Agreement | — | — | — | — | — | — | $300.00K | |||||||||||||||
| Total | $41.45M | $84.68M | $127.39M | $281.72M | $354.57M | $311.63M | $235.09M |
Akebia Therapeutics brought in $235.09M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. Akebia Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $311.63M. Auryxia was the largest at $181.54M (77.2%), ahead of Vafseo at $45.79M (19.5%) and License, Collaboration & Other Revenue at $5.66M (2.4%). The other two lines brought in $2.10M combined.
Compared with fiscal 2024, Auryxia grew 19.3% to $181.54M and License, Collaboration & Other Revenue grew 5.5% to $5.66M.
Akebia Therapeutics began breaking out Auryxia in fiscal 2023, Vafseo in fiscal 2025, License Collaboration & Other Revenue, Royalties in fiscal 2023 and Supply Agreement in fiscal 2025. Akebia Therapeutics stopped reporting Product Revenue, Net ($152.18M in fiscal 2024) and License ($1.00M in fiscal 2023) as separate lines.
Total Proportional Performance Revenue was Akebia Therapeutics’s largest revenue line in fiscal 2021, bringing in $65.48M of $136.85M (48%).
| Counterparty Name | FY 2017 | FY 2018 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|---|---|
| Otsuka Pharmaceutical Co. Ltd | $191.17M | — | — | — | $45.50M | $53.05M | |
| Total Proportional Performance Revenue | — | — | — | — | $154.30M | $65.48M | |
| Mitsubishi Tanabe Pharma Corporation | $9.30M | — | $10.00M | — | $36.83M | $12.51M | |
| Tanabe Pharma Corporation | — | $10.00M | — | $15.00M | — | — | |
| Jt & Torii | $212.00K | — | — | — | $5.70M | $5.81M | |
| Total | $200.68M | $10.00M | $10.00M | $15.00M | $242.33M | $136.85M |
Akebia Therapeutics brought in $136.85M from its four revenue lines in fiscal 2021, the year ended December 31, 2021. That was down 43.5% from $242.33M in fiscal 2020. Total Proportional Performance Revenue was the largest at $65.48M (47.8%), ahead of Otsuka Pharmaceutical Co. Ltd at $53.05M (38.8%) and Mitsubishi Tanabe Pharma Corporation at $12.51M (9.1%). The remaining revenue line, Jt & Torii, brought in $5.81M.
Compared with fiscal 2020, Otsuka Pharmaceutical Co. Ltd grew fastest, up 16.6% to $53.05M, while Mitsubishi Tanabe Pharma Corporation fell the most, down 66.0% to $12.51M.
Akebia Therapeutics began breaking out Total Proportional Performance Revenue in fiscal 2020, when it brought in $154.30M. Akebia Therapeutics stopped reporting Tanabe Pharma Corporation as a separate revenue line after fiscal 2020, when it brought in $15.00M.
As Previously Reported was Akebia Therapeutics’s largest revenue line in fiscal 2022, bringing in $127.39M of $127.14M (100%).
| Restatement | FY 2022 | FY 2022 | FY 2022 |
|---|---|---|---|
| As Previously Reported | $41.45M | $85.15M | $127.39M |
| Adjustment | -$76.00K | -$394.00K | -$250.00K |
| Total | $41.37M | $84.76M | $127.14M |
Akebia Therapeutics brought in $127.14M from its two revenue lines in fiscal 2022, the year ended September 30, 2022. That was up 50.0% from $84.76M in fiscal 2022. As Previously Reported was the largest at $127.39M (100.2%).
The total is net of Adjustment, which took $250.00K off revenue in fiscal 2022.
Akebia Therapeutics (AKBA) reports its revenue by product and service, by counterparty name and by restatement. In fiscal 2025, Auryxia was its largest product and service line, bringing in $181.54M (77.2% of the total), followed by Vafseo at $45.79M (19.5%).
Auryxia was Akebia Therapeutics' largest product and service line in fiscal 2025, bringing in $181.54M, or 77.2% of the $235.09M total across its five product and service lines.
Total Proportional Performance Revenue was Akebia Therapeutics' largest revenue line in fiscal 2021, bringing in $65.48M, or 47.8% of the $136.85M total across its four revenue lines.
Among Akebia Therapeutics' revenue lines that make up at least 2% of revenue, Otsuka Pharmaceutical Co. Ltd grew fastest in fiscal 2021, up 16.6% from $45.50M to $53.05M.
Every figure comes from Akebia Therapeutics' annual financial filings, as reported. Each line keeps the name Akebia Therapeutics gives it, and years follow its fiscal calendar.
Akebia Therapeutics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.